FGFR4 and hepatocellular carcinoma: Yi et al. [62] demonstrated in murine HCC models that lenvatinib blocks FGFR4/GSK3β signalling, suppresses tumour growth, and promotes ubiquitination and proteasomal degradation of PDL-1.